دورية أكاديمية
Variable temperature-nuclear magnetic resonance experiment and high-resolution MS/MS n measurement of hydroxycarbodenafil, and its PDE5 inhibitory activity.
العنوان: | Variable temperature-nuclear magnetic resonance experiment and high-resolution MS/MS n measurement of hydroxycarbodenafil, and its PDE5 inhibitory activity. |
---|---|
المؤلفون: | Tachikawa H; Department of Pharmaceutical Sciences, Tokyo Metropolitan Institute of Public Health, Tokyo, Japan. Electronic address: Hajime_Tachikawa@member.metro.tokyo.jp., Nishiyama R; Department of Pharmaceutical Sciences, Tokyo Metropolitan Institute of Public Health, Tokyo, Japan., Kosugi Y; Department of Pharmaceutical Sciences, Tokyo Metropolitan Institute of Public Health, Tokyo, Japan., Ichikawa-Kaji Y; Department of Pharmaceutical Sciences, Tokyo Metropolitan Institute of Public Health, Tokyo, Japan., Uemura N; Department of Pharmaceutical Sciences, Tokyo Metropolitan Institute of Public Health, Tokyo, Japan., Moriuchi Y; Department of Pharmaceutical Sciences, Tokyo Metropolitan Institute of Public Health, Tokyo, Japan., Moriyasu T; Tokyo Food Sanitation Association Food Research Laboratory, Tokyo, Japan., Suzuki T; Department of Pharmaceutical Sciences, Tokyo Metropolitan Institute of Public Health, Tokyo, Japan., Inomata A; Department of Pharmaceutical Sciences, Tokyo Metropolitan Institute of Public Health, Tokyo, Japan. |
المصدر: | Journal of pharmaceutical and biomedical analysis [J Pharm Biomed Anal] 2024 Aug 15; Vol. 246, pp. 116226. Date of Electronic Publication: 2024 May 15. |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: Elsevier Science Country of Publication: England NLM ID: 8309336 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-264X (Electronic) Linking ISSN: 07317085 NLM ISO Abbreviation: J Pharm Biomed Anal Subsets: MEDLINE |
أسماء مطبوعة: | Publication: <2006->: London : Elsevier Science Original Publication: Oxford ; New York : Pergamon Press, c1983- |
مواضيع طبية MeSH: | Phosphodiesterase 5 Inhibitors*/chemistry , Phosphodiesterase 5 Inhibitors*/analysis , Phosphodiesterase 5 Inhibitors*/pharmacology , Magnetic Resonance Spectroscopy*/methods , Temperature*, Crystallography, X-Ray/methods ; Tandem Mass Spectrometry/methods ; Cyclic Nucleotide Phosphodiesterases, Type 5/metabolism ; Cyclic Nucleotide Phosphodiesterases, Type 5/chemistry ; Piperazines/chemistry ; Piperazines/pharmacology ; Piperazines/analysis |
مستخلص: | Hydroxycarbodenafil, an analogue of carbodenafil, was detected in a dietary supplement in China in 2020. However, previous reports have not identified some carbon signals from the piperazine ring in nuclear magnetic resonance (NMR) experiments. Because the compound contains an amide bond, the reaction was suggested to be characteristic of compounds with rotational isomers. Variable-temperature NMR is used to determine the rotational barrier between different conformations by changing the measurement temperature. Using this technique, we succeeded in obtaining the first distinct data, including the carbon signals of the piperazine ring in the NMR spectrum of hydroxycarbodenafil. We also confirmed that this technique could be applied to other carbodenafil analogues. Multi-stage mass spectrometry (MS n ) measurements with a high-resolution mass spectrometer specific to the substructures were performed to develop a protocol for the structural determination of the carbodenafil analogues. In addition, hydroxycarbodenafil was analysed using X-ray crystallography, and its inhibitory activity against phosphodiesterase type 5 (PDE5) was measured. The IC Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (Copyright © 2024 Elsevier B.V. All rights reserved.) |
فهرسة مساهمة: | Keywords: Dietary supplement; HRMS/MS(n); Hydroxycarbodenafil; Phosphodiesterase-5 inhibitor; VT-NMR; X-ray crystallography |
المشرفين على المادة: | 0 (Phosphodiesterase 5 Inhibitors) EC 3.1.4.35 (Cyclic Nucleotide Phosphodiesterases, Type 5) 0 (Piperazines) |
تواريخ الأحداث: | Date Created: 20240524 Date Completed: 20240609 Latest Revision: 20240618 |
رمز التحديث: | 20240618 |
DOI: | 10.1016/j.jpba.2024.116226 |
PMID: | 38788623 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1873-264X |
---|---|
DOI: | 10.1016/j.jpba.2024.116226 |